Background
==========

Glucocorticoids such as prednisolone and dexamethasone are critical components of multi-agent chemotherapy protocols used in the treatment of acute lymphoblastic leukemia (ALL) \[[@B1]\] due to their ability to induce apoptosis in lymphoid cells. Despite their use for over 50 years their mechanism of action is not completely understood. Glucocorticoids are steroid hormones that act on target cells through interaction with a specific glucocorticoid receptor (GR) \[[@B2]\]. The GR is held in a cytosolic complex by a number of co-chaperone molecules including HSP-90 and HSP-70 \[[@B3]\], and on ligand binding dissociates from the co-chaperone complex, dimerizes and is transported to the nucleus where it binds to palindromic DNA sequences known as glucocorticoid response elements (GREs) found in the promoter regions of target genes \[[@B4]\]. This leads to the activation of transcription of primary target genes, repression of transcription through interaction with negative GREs \[[@B5]\] or of gene activation through transcription factors such as AP-1 and NF-ΚB \[[@B6]\]. In lymphoid cells, this results in repression of cell cycle progression through cyclin-D3 and C-MYC \[[@B7]\], and cell death through the activation of apoptosis. Glucocorticoids also induce other non-apoptotic mechanisms of programmed cell death including autophagy \[[@B8]\] and mediate a number of pathways involved in the metabolism of carbohydrates, lipids and proteins.

A number of studies have published microarray data of glucocorticoid-induced genes in lymphoid cells, but comparison of the data is complicated by technical differences in platform and chip type. Previous studies of glucocorticoid-induced genes in ALL have been carried out using *in vitro*cell-line models \[[@B9]-[@B15]\] and patient-derived cells, both *in vivo*\[[@B16]\] and *in vitro*\[[@B17]\]. Cell lines are extensively used in the study of ALL but in the process of immortalization acquire multiple genetic defects, particularly in the p53 pathway \[[@B18]\], and mechanisms demonstrated in cell lines are often not replicated in more clinically relevant models. Primary patient cells have a finite supply and rarely survive *ex vivo*for more than a few days. The non-obese diabetic/severe combined immunodeficient (NOD/SCID) xenograft mouse model is widely used to study ALL. In this model, human leukemia cells obtained from diagnostic bone marrow biopsies are inoculated into NOD/SCID mice, and on engraftment establish a systemic leukemia which retains the fundamental biological characteristics of the original disease \[[@B19]\]. It has also been shown that the *in vivo*responses to chemotherapeutic agents, including dexamethasone, correlates with patient outcome \[[@B20]\], and thus the NOD/SCID xenograft mouse model provides a stable, reproducible and clinically relevant model with which to study ALL. Here we report the first study investigating glucocorticoid-induced gene expression in ALL using the NOD/SCID xenograft model, the optimal experimental design, and a comparison of our microarray data to publicly available datasets of glucocorticoid-induced genes in other experimental models.

Methods
=======

NOD/SCID xenograft mouse model
------------------------------

All experimental studies were approved by the Human Research Ethics Committee and the Animal Care and Ethics Committee of the University of New South Wales. ALL-3, a glucocorticoid-sensitive xenograft derived from a 12 year old girl with mixed lineage leukemia (MLL)-rearranged BCP-ALL, was chosen for this study. Although MLL-rearranged ALL is associated with a poor prednisolone response and an inferior outcome \[[@B21]\], this patient is currently a long-term survivor. ALL-3 demonstrates *in vitro*glucocorticoid sensitivity, with an IC~50~of 9.4 nM on exposure to dexamethasone. In the *in vivo*NOD/SCID xenograft mouse model, ALL-3 is highly responsive to 4 weeks of treatment with single agent dexamethasone, with rapid clearance of leukemic blasts from the peripheral blood and recurrence of leukemia delayed by 63.4 days compared to vehicle-treated controls \[[@B20]\].

Cells from ALL-3 were inoculated by tail-vein injection into 28 NOD/SCID mice. The mice were bled weekly and the samples stained with fluorescein isothiocyanate (FITC)-conjugated anti-murine CD45 and allophycocyanin (APC)-conjugated anti-human CD45 (BioLegend, San Diego, CA). Following lysis of erythrocytes with FACS lysing solution (BD Biosciences, San Jose, CA), samples were analyzed by multiparametric flow cytometry on a FACSCanto cytometer (BD Biosciences, San Jose, CA). Engraftment was calculated as the proportion of human versus total CD45^+^cells.

When high level (\> 70%) engraftment was achieved in the peripheral blood, between 8 and 10 weeks post-transplantation, the mice were randomized and split into groups of 4 to receive either dexamethasone 15 mg/kg (Sigma-Aldrich, St Louis, MO) or vehicle control by intraperitoneal injection. Mice were culled by CO~2~asphyxiation at 0 hours (pre-treatment, group 1), 8 hours (groups 2 and 3), 24 hours (groups 4 and 5) or 48 hours (groups 6 and 7) following treatment. The mice in groups 6 and 7 received a second dose of dexamethasone or vehicle control at 24 hours. Two mice succumbed early to thymoma, a well-recognized complication in NOD/SCID mice, resulting in 3 mice in each of groups 6 and 7. Cell suspensions of spleens were prepared and mononuclear cells enriched and purified to \> 97% human by density gradient centrifugation using LymphoPrep (Axis-Shield, Norway), and cell viability assessed by trypan blue exclusion. RNA was extracted using the RNeasy mini kit (Qiagen, Hilden, Germany) and the RNA integrity verified (Agilent Bioanalyzer, Santa Clara, CA). The RNA was amplified using the Illumina TotalPrep RNA amplification kit (Ambion, Austin, TX) and hybridized onto Illumina WG-6_V3 chips (Illumina, San Diego, CA). The chips were scanned on the Illumina Bead Array Reader (Illumina, San Diego, CA) and gene expression analyzed. The data have been deposited in NCBI\'s Gene Expression Omnibus \[[@B22]\] and are accessible through GEO Series accession number GSE30392 <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30392>.

Gene expression and functional analysis
---------------------------------------

The sample probe profiles with no normalization or background correction were exported from BeadStudio (version 3.0.14, Illumina, San Diego, CA). The data were pre-processed using variance stabilizing transformation \[[@B23]\] and robust spline normalization in lumi \[[@B24]\] which takes advantage of each probe being represented by \> 25 beads. Differential gene expression was determined using limma \[[@B25]\] by comparing all treated groups to time 0 hours, with the positive False Discovery Rate correction for multiple testing \[[@B26]\]. Complete linkage hierarchical clustering using Euclidian distance was used to compare groups to each other. Functional analysis was performed using gene set enrichment analysis (GSEA) version 2.04 \[[@B27]\], comparing the limma moderated t-statistic for each probe in a pre-ranked file, against the c2_all collection of gene sets from the Molecular Signatures Database \[[@B27]\] version 2.5 with 1000 permutations. The similarity of the top 100 up- and down-regulated genesets was assessed using meta-GSEA (Cowley *et al*, manuscript in preparation).

Comparison of models
--------------------

The molecular response to glucocorticoids in xenografts was compared to publicly available microarray data \[[@B13],[@B16]\] using parametric analysis of gene set enrichment \[[@B28]\] implemented in the PGSEA package (version 1.20.1, Furge and Dykema) from the Bioconductor project \[[@B29]\], with some modifications to the algorithm to assess significance of the genes that are in the geneset *and represented on the microarray*, and to allow more control over control sample specification (available upon request). Expression levels of each gene in each sample were converted to expression ratios relative to patient matched controls before glucocorticoid treatment (Schmidt *et al*), time-matched controls (Rainer *et al*), or time 0 hours (xenografts). Within each dataset, these gene-level ratios were summarized into geneset-level Z-scores, using PGSEA with genesets from the c2_all collection \[[@B27]\]. The Z-scores from each sample from the 3 studies were combined and then compared by hierarchical clustering of the top 100 gene sets demonstrating the greatest variance across the combined studies.

Replicate analysis
------------------

The stability of results when reducing the number of replicates was assessed using the Recovery Score method \[[@B30]\] from the GeneSelector package (version 1.4.0) of the Bioconductor project \[[@B29]\].

Results and Discussion
======================

It has been demonstrated that changes in gene expression can be detected as early as 6 hours after treatment of ALL with glucocorticoids *in vivo*\[[@B16]\] and *in vitro*\[[@B11]\], although earlier timepoints show few, if any, significantly differentially expressed genes \[[@B17]\]. In this study the 8 hour dexamethasone-treated timepoint demonstrated the highest number of differentially expressed genes compared to baseline control, with far fewer observed at the 24 and 48 hour dexamethasone-treated timepoints (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}, and Figure [1](#F1){ref-type="fig"}). Whilst a similar proportion of up- and down-regulated genes were identified at the 8 hour dexamethasone-treated timepoint (1158 vs 1072 respectively, FDR \< 0.05), of those with large fold changes (FC \> 2 or FC \< 0.5, red dots in Figure [1A](#F1){ref-type="fig"}), 75% were up regulated (199 vs 65 respectively), consistent with the predominant role of glucocorticoids as transcriptional activators. The large numbers of statistically differentially expressed genes (FDR \< 0.05) with small fold changes (0.5 \< FC \< 2) are indicative of both small measurement error across replicates, and thus the high reproducibility of the xenograft model, and good experimental power resulting from using 4 replicates. There was minimal significant differential gene expression across the time-matched controls (Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}). This demonstrates that in the xenograft mouse model, the 8 hour timepoint provides the greatest information, and that these changes are not sustained over later timepoints. The handling of the mice and intraperitoneal vehicle control injections had minimal effect on gene expression, and thus time-matched controls are redundant.

###### 

Number of differentially expressed genes by False Discovery Rate (FDR), compared to time 0 hours.

  Timepoint (hours)   FDR \< 0.25   FDR \< 0.1   FDR \< 0.05                 
  ------------------- ------------- ------------ ------------- ------ ------ ------
  **Dex 8**           2313          2434         1470          1423   1158   1072
  **Dex 24**          970           1087         273           421    75     195
  **Dex 48**          321           327          41            95     12     44
  **Con 8**           0             0            0             0      0      0
  **Con 24**          0             1            0             1      0      1
  **Con 48**          0             1            0             1      0      1

**+**upregulated; **-**downregulated; Dex, dexamethasone-treated; and Con, control

###### 

Number of differentially expressed genes by Fold Change (FC), compared to time 0 hours.

  Timepoint (hours)   FC \> 1.5   FC \> 2   FC \> 4             
  ------------------- ----------- --------- --------- ---- ---- ---
  **Dex 8**           501         429       201       68   38   0
  **Dex 24**          137         341       15        90   0    0
  **Dex 48**          79          234       5         69   0    3
  **Con 8**           1           37        1         2    0    0
  **Con 24**          1           5         0         0    0    0
  **Con 48**          7           34        0         2    0    0

**+**upregulated; **-**downregulated; Dex, dexamethasone-treated; and Con, control

![**Volcano plots of significantly differentially expressed genes following treatment with dexamethasone at 8 hours (A), 24 hours (B), 48 hours (C)**. Significance was defined as log2 Fold Change \> 1 or \< -1 with False Discovery Rate (FDR) \< 0.05. Each dot represents a single gene, and significant genes indicated by red dots.](1471-2164-12-565-1){#F1}

At the 8 hour timepoint, there were 173 genes upregulated with a t-statistic (the ratio of fold change to standard error) \> 10 and 25 genes downregulated with a t-statistic \< -10 (corresponding to P \< 1.74 × 10^-9^and FDR \< 2.95 × 10^-7^, table [3](#T3){ref-type="table"}). None of these genes had sustained expression changes at 24 or 48 hours, and although this could potentially reflect the early death of sensitive cells, there was no significant difference in the total number of cells harvested from the spleens at any timepoint compared to the time-matched controls (data not shown), and all harvests had a cell viability of ≥ 96%.

###### 

Genes regulated 8 hours following dexamethasone treatment.

  ProbeSet ID         Gene        t        P            FDR          Definition
  ------------------- ----------- -------- ------------ ------------ --------------------------------------------------------------
  **Upregulated**                                                    
  ILMN_5080450        ZBTB16      83.77    \< 2.2E-16   \< 2.2E-16   zinc finger and BTB domain containing 16
  ILMN_3800088        MMP7        53.22    \< 2.2E-16   \< 2.2E-16   matrix metallopeptidase 7
  ILMN_1770593        CH25H       53.14    \< 2.2E-16   \< 2.2E-16   cholesterol 25-hydroxylase
  ILMN_6560328        C6orf85     44.60    \< 2.2E-16   \< 2.2E-16   chromosome 6 open reading frame 85
  ILMN_7570561        TSC22D3     39.16    \< 2.2E-16   \< 2.2E-16   TSC22 domain family, member 3
  ILMN_580187         PDE8B       33.88    \< 2.2E-16   3.90E-16     phosphodiesterase 8B
  ILMN_5130066        C8orf61     33.82    \< 2.2E-16   3.90E-16     chromosome 8 open reading frame 61
  ILMN_4120431        TMEM100     31.38    \< 2.2E-16   1.64E-15     transmembrane protein 100
  ILMN_650553         BIN1        29.76    \< 2.2E-16   4.43E-15     bridging integrator 1
  ILMN_1400373        SLA         29.57    \< 2.2E-16   4.63E-15     Src-like-adaptor
  ILMN_6330593        PTHR1       29.28    \< 2.2E-16   5.22E-15     parathyroid hormone receptor 1
  ILMN_6110037        LILRA3      29.04    \< 2.2E-16   5.75E-15     leukocyte immunoglobulin-like receptor subfamily A, member 3
  ILMN_4150477        LOXL4       28.67    \< 2.2E-16   6.66E-15     lysyl oxidase-like 4
  ILMN_2680079        OGFRL1      28.65    \< 2.2E-16   6.66E-15     opioid growth factor receptor-like 1
  ILMN_4210411        NDRG2       28.20    \< 2.2E-16   8.62E-15     NDRG family member 2
  ILMN_3780093        LILRA1      27.86    \< 2.2E-16   1.05E-14     leukocyte immunoglobulin-like receptor subfamily A, member 1
  ILMN_240441         IL1R2       27.46    \< 2.2E-16   1.33E-14     interleukin 1 receptor, type II
  ILMN_4730315        MERTK       26.14    \< 2.2E-16   3.31E-14     c-mer proto-oncogene tyrosine kinase
  ILMN_3800538        ACPL2       25.90    \< 2.2E-16   3.72E-14     acid phosphatase-like 2
  ILMN_6860392        UGT2B17     25.83    \< 2.2E-16   3.72E-14     UDP glucuronosyltransferase 2 family, polypeptide B17
  ILMN_4730541        SLC44A1     25.82    \< 2.2E-16   3.72E-14     solute carrier family 44, member 1
  ILMN_4860546        CTHRC1      25.64    \< 2.2E-16   4.10E-14     collagen triple helix repeat containing 1
  ILMN_3460270        ZHX3        24.56    \< 2.2E-16   8.79E-14     zinc fingers and homeoboxes 3
  ILMN_10639          RASSF4      23.21    \< 2.2E-16   2.57E-13     Ras association (RalGDS/AF-6) domain family 4
  ILMN_1190064        UGT2B7      23.13    \< 2.2E-16   2.67E-13     UDP glucuronosyltransferase 2 family, polypeptide B7
  ILMN_6400603        MGC2463     23.06    \< 2.2E-16   2.71E-13     poliovirus receptor related immunoglobulin domain containing
  ILMN_3450187        IRGM        23.04    \< 2.2E-16   2.71E-13     immunity-related GTPase family, M
  ILMN_6620528        MT1X        22.95    2.40E-16     2.85E-13     metallothionein 1X
  ILMN_1260341        IL13RA1     22.47    3.67E-16     4.13E-13     interleukin 13 receptor, alpha 1
  ILMN_2650112        SLC16A2     22.25    4.48E-16     4.91E-13     solute carrier family 16, member 2
  ILMN_5570170        PNMT        22.01    5.59E-16     5.95E-13     phenylethanolamine N-methyltransferase
  ILMN_870376         C9orf152    21.93    6.02E-16     6.25E-13     chromosome 9 open reading frame 152
  ILMN_3190379        TGFBR3      21.52    8.78E-16     8.89E-13     transforming growth factor, beta receptor III
  ILMN_1780142        DSCR1       21.08    1.33E-15     1.31E-12     Down syndrome critical region gene 1
  ILMN_2640341        FKBP5       20.63    2.05E-15     1.89E-12     FK506 binding protein 5
  ILMN_7610136        LOC652626   20.43    2.48E-15     2.23E-12     Leukocyte immunoglobulin-like receptor subfamily B member 2
  ILMN_1410609        CORO2A      20.34    2.72E-15     2.35E-12     coronin, actin binding protein, 2A
  ILMN_1780088        TBXA2R      20.29    2.84E-15     2.40E-12     thromboxane A2 receptor
  ILMN_270431         BAALC       20.23    3.02E-15     2.50E-12     brain and acute leukemia, cytoplasmic
  ILMN_6280176        GBE1        20.02    3.72E-15     3.01E-12     glucan (1,4-alpha-), branching enzyme 1
  ILMN_6060113        TBX15       19.81    4.62E-15     3.67E-12     T-box 15
  ILMN_4890743        IQSEC1      19.71    5.09E-15     3.97E-12     IQ motif and Sec7 domain 1
  ILMN_150056         DPEP1       19.65    5.41E-15     4.13E-12     dipeptidase 1
  ILMN_2060364        BTNL9       19.26    8.04E-15     5.91E-12     butyrophilin-like 9
  ILMN_3830735        UPB1        19.23    8.30E-15     5.91E-12     ureidopropionase, beta
  ILMN_5670377        STYK1       19.15    9.09E-15     6.35E-12     serine/threonine/tyrosine kinase 1
  ILMN_4390630        STAG3       18.72    1.42E-14     9.39E-12     stromal antigen 3
  ILMN_4070048        NPHP4       18.44    1.91E-14     1.25E-11     nephronophthisis 4
  ILMN_4220474        C6orf81     18.31    2.16E-14     1.39E-11     chromosome 6 open reading frame 81
  ILMN_1470746        PTPN3       18.30    2.23E-14     1.41E-11     protein tyrosine phosphatase, non-receptor type 3
  ILMN_5860576        C20orf133   18.25    2.36E-14     1.47E-11     MACRO domain containing 2
  ILMN_6020468        PPP1R14A    18.18    2.52E-14     1.55E-11     protein phosphatase 1, regulatory (inhibitor) subunit 14A
  ILMN_1400634        MT1M        18.10    2.76E-14     1.64E-11     metallothionein 1M
  ILMN_4250315        ITGA9       17.90    3.46E-14     2.03E-11     integrin, alpha 9
  ILMN_5080471        MAP3K6      17.40    6.02E-14     3.44E-11     mitogen-activated protein kinase 6
  ILMN_5360242        FLJ42461    17.36    6.28E-14     3.53E-11     smoothelin-like 2
  ILMN_6620402        NUDT16      17.33    6.50E-14     3.60E-11     nudix (nucleoside diphosphate linked moiety X)-type motif 16
  ILMN_3360112        TMEM2       17.26    7.04E-14     3.85E-11     transmembrane protein 2
  ILMN_6840743        PER1        17.22    7.41E-14     3.99E-11     period homolog 1
  ILMN_4220347        LRRC1       17.12    8.29E-14     4.33E-11     leucine rich repeat containing 1
  ILMN_4850592        P2RY14      17.11    8.35E-14     4.33E-11     purinergic receptor P2Y, G-protein coupled, 14
  ILMN_6560300        SLC31A2     16.91    1.05E-13     5.39E-11     solute carrier family 31 member 2
  ILMN_4060091        DKFZ        16.87    1.11E-13     5.62E-11     DKFZp451A211 protein
  ILMN_6770370        LOC92196    16.28    2.23E-13     1.11E-10     death associated protein-like 1
  ILMN_580487         IL9R        16.21    2.40E-13     1.18E-10     interleukin 9 receptor
  ILMN_1990300        SOCS1       16.18    2.49E-13     1.21E-10     suppressor of cytokine signaling 1
  ILMN_5720424        NRP1        16.17    2.54E-13     1.22E-10     neuropilin 1
  ILMN_4180427        CIB4        16.11    2.74E-13     1.30E-10     calcium and integrin binding family member 4
  ILMN_4180544        ROPN1L      16.08    2.81E-13     1.32E-10     ropporin 1-like
  ILMN_4250167        SOX13       16.04    2.95E-13     1.37E-10     SRY (sex determining region Y)-box 13
  ILMN_6330170        CHKA        15.81    3.94E-13     1.81E-10     choline kinase alpha, 3
  ILMN_4560192        SFXN5       15.62    4.95E-13     2.25E-10     sideroflexin 5
  ILMN_2810136        CAPN11      15.56    5.33E-13     2.40E-10     calpain 11
  ILMN_2690709        VIPR1       15.38    6.68E-13     2.91E-10     vasoactive intestinal peptide receptor 1
  ILMN_630091         NCOA7       15.38    6.69E-13     2.91E-10     nuclear receptor coactivator 7
  ILMN_5390730        MGC17330    15.21    8.25E-13     3.55E-10     phosphoinositide-3-kinase interacting protein 1
  ILMN_130364         MST150      15.19    8.49E-13     3.62E-10     MSTP150
  ILMN_3450241        KIAA0774    14.95    1.16E-12     4.77E-10     KIAA0774
  ILMN_2230678        ACACB       14.80    1.41E-12     5.76E-10     acetyl-Coenzyme A carboxylase beta
  ILMN_5870307        LOC440359   14.78    1.44E-12     5.83E-10     similar to muscle Y-box protein YB2
  ILMN_3840554        SPOCK2      14.76    1.49E-12     5.95E-10     sparc/osteonectin, cwcv and kazal-like domains 2
  ILMN_5810600        MAP3K5      14.69    1.63E-12     6.47E-10     mitogen-activated protein kinase 5
  ILMN_2360719        IRAK3       14.65    1.71E-12     6.65E-10     interleukin-1 receptor-associated kinase 3
  ILMN_1510121        MTSS1       14.64    1.73E-12     6.66E-10     metastasis suppressor 1
  ILMN_540671         LILRB2      14.54    1.98E-12     7.41E-10     leukocyte immunoglobulin-like receptor subfamily B, member 2
  ILMN_6980377        MTMR15      14.44    2.26E-12     8.39E-10     myotubularin related protein 15
  ILMN_6220288        PRDM1       14.43    2.28E-12     8.39E-10     PR domain containing 1, with ZNF domain
  ILMN_7330739        NDRG4       14.42    2.30E-12     8.39E-10     NDRG family member 4
  ILMN_2600470        WDR60       14.20    3.10E-12     1.12E-09     WD repeat domain 60
  ILMN_4050441        SH3MD4      14.16    3.27E-12     1.17E-09     SH3 multiple domains 4
  ILMN_6760546        TIPARP      13.89    4.74E-12     1.64E-09     TCDD-inducible poly(ADP-ribose) polymerase
  ILMN_2760537        MTE         13.89    4.75E-12     1.64E-09     metallothionein E
  ILMN_160019         SORT1       13.79    5.44E-12     1.83E-09     sortilin 1
  ILMN_6330132        ISG20       13.60    7.00E-12     2.32E-09     interferon stimulated exonuclease gene 20 kDa
  ILMN_1510685        DOK4        13.52    7.86E-12     2.58E-09     docking protein 4
  ILMN_1240228        PAG1        13.47    8.50E-12     2.77E-09     phosphoprotein associated glycosphingolipid microdomains 1
  ILMN_580592         CPNE8       13.32    1.04E-11     3.31E-09     copine VIII
  ILMN_5870301        KIAA0513    13.32    1.05E-11     3.31E-09     KIAA0513
  ILMN_20129          CD52        13.32    1.05E-11     3.31E-09     CD52 molecule
  ILMN_1820386        PARVB       13.31    1.06E-11     3.31E-09     parvin, beta
  ILMN_6200402        MT1A        13.24    1.17E-11     3.64E-09     metallothionein 1A
  ILMN_290661         CLN8        13.10    1.43E-11     4.36E-09     ceroid-lipofuscinosis, neuronal 8
  ILMN_670082         GNA12       13.08    1.47E-11     4.43E-09     guanine nucleotide binding protein (G protein) alpha 12
  ILMN_5570286        TACC2       12.99    1.67E-11     5.00E-09     transforming, acidic coiled-coil containing protein 2
  ILMN_3190411        STARD13     12.93    1.81E-11     5.32E-09     START domain containing 13
  ILMN_4540138        NGB         12.92    1.85E-11     5.39E-09     neuroglobin
  ILMN_2000646        B4GALT4     12.83    2.10E-11     6.07E-09     UDP-galactosyltransferase, polypeptide 4
  ILMN_7100731        CYGB        12.81    2.17E-11     6.17E-09     cytoglobin
  ILMN_7050113        NTRK1       12.71    2.52E-11     7.09E-09     neurotrophic tyrosine kinase receptor, type 1
  ILMN_2490670        GNPTAB      12.66    2.71E-11     7.52E-09     N-acetylglucosamine-1-phosphate transferase, alpha and beta
  ILMN_20170          ZNF385      12.48    3.55E-11     9.72E-09     zinc finger protein 385
  ILMN_2630687        CHPT1       12.43    3.80E-11     1.02E-08     choline phosphotransferase 1
  ILMN_4120215        WASF2       12.43    3.81E-11     1.02E-08     WAS protein family, member 2
  ILMN_5260494        TMLHE       12.39    4.06E-11     1.08E-08     trimethyllysine hydroxylase, epsilon
  ILMN_5220333        C14orf139   12.31    4.54E-11     1.20E-08     chromosome 14 open reading frame 139
  ILMN_3850440        FCER1G      12.12    6.07E-11     1.60E-08     Fc fragment of IgE, receptor for; gamma polypeptide
  ILMN_1030008        TGFB3       12.11    6.21E-11     1.63E-08     transforming growth factor, beta 3
  ILMN_1450468        MYT1        12.02    7.04E-11     1.81E-08     myelin transcription factor 1
  ILMN_7560541        SLC2A5      12.01    7.19E-11     1.83E-08     solute carrier family 2 member 5
  ILMN_2030438        GBA2        12.01    7.21E-11     1.83E-08     glucosidase, beta (bile acid) 2
  ILMN_6840328        SMAD3       12.00    7.35E-11     1.86E-08     SMAD family member 3
  ILMN_3930390        SMAP1L      11.91    8.40E-11     2.11E-08     stromal membrane-associated protein 1-like
  ILMN_7570196        TSPAN9      11.90    8.54E-11     2.12E-08     tetraspanin 9
  ILMN_6980546        CACNA1I     11.90    8.56E-11     2.12E-08     calcium channel, voltage-dependent, T type, alpha 1I subunit
  ILMN_1710364        LCN6        11.89    8.72E-11     2.15E-08     lipocalin 6
  ILMN_5360424        RPS6KA2     11.77    1.04E-10     2.54E-08     ribosomal protein S6 kinase, 90 kDa, polypeptide 2
  ILMN_5890193        MS4A4A      11.72    1.14E-10     2.75E-08     membrane-spanning 4-domains, subfamily A, member 4
  ILMN_3390292        KLF9        11.66    1.24E-10     2.98E-08     Kruppel-like factor 9
  ILMN_5720059        GFOD1       11.65    1.26E-10     3.02E-08     glucose-fructose oxidoreductase domain containing 1
  ILMN_7650523        TMEM46      11.57    1.43E-10     3.39E-08     transmembrane protein 46
  ILMN_5700392        LOC654000   11.46    1.70E-10     3.95E-08     ribosome biogenesis protein BMS1 homolog 2
  ILMN_4810348        C1orf188    11.40    1.88E-10     4.33E-08     chromosome 1 open reading frame 188
  ILMN_4280180        CHRNA3      11.39    1.91E-10     4.37E-08     cholinergic receptor, nicotinic, alpha 3
  ILMN_270458         CRISPLD1    11.37    1.96E-10     4.45E-08     cysteine-rich secretory protein LCCL domain containing 1
  ILMN_450615         MT2A        11.37    1.97E-10     4.46E-08     metallothionein 2A
  ILMN_20470          GRASP       11.35    2.02E-10     4.51E-08     GRP1-associated scaffold protein
  ILMN_3370594        LILRA2      11.35    2.03E-10     4.51E-08     leukocyte immunoglobulin-like receptor subfamily A, member 2
  ILMN_5220397        RREB1       11.34    2.05E-10     4.53E-08     ras responsive element binding protein 1
  ILMN_1410192        TDRD9       11.34    2.07E-10     4.56E-08     tudor domain containing 9
  ILMN_4070259        LOC653133   11.27    2.30E-10     4.99E-08     guanine nucleotide binding protein (G protein) alpha 12
  ILMN_5960682        RBPMS2      11.24    2.41E-10     5.21E-08     RNA binding protein with multiple splicing 2
  ILMN_1440300        SLC27A3     11.22    2.50E-10     5.37E-08     solute carrier family 27, member 3
  ILMN_5050768        LONRF1      11.20    2.58E-10     5.53E-08     LON peptidase N-terminal domain and ring finger 1
  ILMN_6270273        KHDRBS3     11.18    2.67E-10     5.68E-08     KH domain, RNA binding, signal transduction associated 3
  ILMN_7100603        KCNK3       11.17    2.70E-10     5.72E-08     potassium channel, subfamily K, member 3
  ILMN_2320129        CSDA        11.03    3.38E-10     7.08E-08     cold shock domain protein A
  ILMN_3930022        LOC644739   10.99    3.63E-10     7.54E-08     Wiskott-Aldrich syndrome protein family member 4
  ILMN_7400133        CUGBP2      10.90    4.20E-10     8.63E-08     CUG triplet repeat, RNA binding protein 2
  ILMN_3290301        FZD8        10.88    4.33E-10     8.76E-08     frizzled homolog 8
  ILMN_7320520        MTUS1       10.88    4.33E-10     8.76E-08     mitochondrial tumor suppressor 1
  ILMN_3780053        PALLD       10.82    4.79E-10     9.60E-08     palladin, cytoskeletal associated protein
  ILMN_6860162        LOC441019   10.74    5.49E-10     1.09E-07     hypothetical LOC441019
  ILMN_5810154        ALOX15B     10.74    5.50E-10     1.09E-07     arachidonate 15-lipoxygenase, type B
  ILMN_3930736        CHST3       10.73    5.59E-10     1.09E-07     carbohydrate (chondroitin 6) sulfotransferase 3
  ILMN_60470          STX11       10.72    5.68E-10     1.10E-07     syntaxin 11
  ILMN_3390484        SERINC2     10.69    5.95E-10     1.15E-07     serine incorporator 2
  ILMN_1430647        TAX1BP3     10.61    6.82E-10     1.31E-07     Tax1 (human T-cell leukemia virus type I) binding protein 3
  ILMN_5960440        VDR         10.60    6.99E-10     1.34E-07     vitamin D (1,25-dihydroxyvitamin D3) receptor
  ILMN_6290735        EPHB3       10.51    8.10E-10     1.53E-07     EPH receptor B3
  ILMN_2680372        SH2D4A      10.46    8.78E-10     1.64E-07     SH2 domain containing 4A
  ILMN_2480050        SOX7        10.44    9.13E-10     1.69E-07     SRY (sex determining region Y)-box 7
  ILMN_130128         LOC285016   10.41    9.61E-10     1.76E-07     hypothetical protein LOC285016
  ILMN_4890451        GRAMD3      10.39    9.87E-10     1.80E-07     GRAM domain containing 3
  ILMN_770161         C10orf73    10.39    9.92E-10     1.81E-07     chromosome 10 open reading frame 73
  ILMN_2450202        KIF3C       10.35    1.05E-09     1.88E-07     kinesin family member 3C
  ILMN_6840468        HAL         10.35    1.06E-09     1.89E-07     histidine ammonia-lyase
  ILMN_2470070        TBL1X       10.30    1.15E-09     2.04E-07     transducin (beta)-like 1X-linked
  ILMN_2320114        KLF13       10.27    1.22E-09     2.15E-07     Kruppel-like factor 13
  ILMN_6380112        DIP         10.23    1.31E-09     2.27E-07     death-inducing-protein
  ILMN_2470358        IFNGR1      10.22    1.32E-09     2.30E-07     interferon gamma receptor 1
  ILMN_4250735        IL27RA      10.07    1.70E-09     2.91E-07     interleukin 27 receptor, alpha
  ILMN_1470215        MAP3K8      10.07    1.72E-09     2.91E-07     mitogen-activated protein kinase 8
  ILMN_2940373        TACC1       10.06    1.74E-09     2.94E-07     transforming, acidic coiled-coil containing protein 1
  **Downregulated**                                                  
  ILMN_770538         LYSMD2      -15.49   5.81E-13     2.58E-10     LysM, putative peptidoglycan-binding, domain containing 2
  ILMN_7150059        STAMBPL1    -14.61   1.79E-12     6.84E-10     STAM binding protein-like 1
  ILMN_5340692        STRBP       -14.56   1.93E-12     7.31E-10     spermatid perinuclear RNA binding protein
  ILMN_4210397        GLDC        -14.05   3.80E-12     1.34E-09     glycine dehydrogenase
  ILMN_6980327        DKC1        -13.79   5.44E-12     1.83E-09     dyskeratosis congenita 1, dyskerin
  ILMN_50086          TCF12       -13.23   1.19E-11     3.69E-09     transcription factor 12
  ILMN_4860356        BYSL        -12.81   2.17E-11     6.17E-09     bystin-like
  ILMN_4280228        IVNS1ABP    -12.70   2.55E-11     7.12E-09     influenza virus NS1A binding protein
  ILMN_1990379        SLFN11      -11.82   9.63E-11     2.36E-08     schlafen family member 11
  ILMN_5220338        MPEG1       -11.64   1.27E-10     3.03E-08     macrophage expressed gene 1
  ILMN_450168         SFRS7       -11.50   1.60E-10     3.74E-08     splicing factor, arginine/serine-rich 7, 35 kDa
  ILMN_3460687        KIAA0690    -11.42   1.81E-10     4.19E-08     ribosomal RNA processing 12 homolog
  ILMN_3400360        MAPRE2      -11.36   1.99E-10     4.48E-08     microtubule-associated protein, RP/EB family, member 2
  ILMN_4010414        PPFIBP1     -11.12   2.92E-10     6.16E-08     PTPRF interacting protein, binding protein 1 (liprin beta 1)
  ILMN_1190139        UGT3A2      -10.99   3.61E-10     7.54E-08     UDP glycosyltransferase 3 family, polypeptide A2
  ILMN_4150201        BCL2        -10.93   3.99E-10     8.24E-08     B-cell CLL/lymphoma 2
  ILMN_780240         C12orf24    -10.85   4.53E-10     9.13E-08     chromosome 12 open reading frame 24
  ILMN_6760167        MARCH3      -10.73   5.60E-10     1.09E-07     membrane-associated ring finger (C3HC4) 3
  ILMN_3940615        PUS7        -10.52   7.99E-10     1.52E-07     pseudouridylate synthase 7 homolog
  ILMN_20544          GART        -10.41   9.53E-10     1.76E-07     phosphoribosylglycinamide formyltransferase
  ILMN_2480326        HSP90B1     -10.36   1.05E-09     1.88E-07     heat shock protein 90 kDa beta (Grp94), member 1
  ILMN_5270367        CTSC        -10.25   1.26E-09     2.20E-07     cathepsin C
  ILMN_5420095        MYC         -10.21   1.36E-09     2.34E-07     v-myc myelocytomatosis viral oncogene homolog
  ILMN_4610180        PIK3C2B     -10.20   1.38E-09     2.37E-07     phosphoinositide-3-kinase, class 2, beta polypeptide
  ILMN_6450300        GEMIN4      -10.00   1.95E-09     3.27E-07     gem (nuclear organelle) associated protein 4

t, t-statistic; and FDR, false discovery rate

The most significantly differentially expressed gene at the 8 hour dexamethasone-treated timepoint was *ZBTB16*, a known transcriptional repressor and glucocorticoid response gene, which has been shown to modulate glucocorticoid sensitivity in CEM T-ALL cells \[[@B31]\]. Other known glucocorticoid response genes upregulated included *TSC22D3*\[[@B32]\] and *SOCS1*\[[@B15]\], both downstream targets of the glucocorticoid receptor, *FKBP5*\[[@B33]\], a co-chaperone of the glucocorticoid receptor, and MAP kinases 5, 6 and 8 \[[@B34]\]. Downregulated genes at 8 hours included *BCL-2*\[[@B35]\] and *C-MYC*\[[@B36]\], both previously described, but also *HSP90B1*, a glucocorticoid receptor co-chaperone and regulator of apoptosis. The only pro-apoptotic gene consistently upregulated across multiple microarray analyses is the BH3-only BCL-2 family member *BIM*, and it has been shown that BIM has a critical role in glucocorticoid sensitivity and resistance \[[@B37]\], although in this current study *BIM*was only induced 1.3 fold. Thus these genes identified are consistent with previous reports of glucocorticoid-induced genes in ALL. Within these experimental systems however there are significant potential differences in glucocorticoid exposure between *in vitro*and *in vivo*models - a crucial one is that cells *in vitro*are continuously exposed to glucocorticoid whereas in *in vivo*models the glucocorticoid is subject to pharmacokinetic and pharmacodynamic changes which more accurately reflect changes in patients.

At the later timepoints, significant differential gene expression was much less marked and predominantly downregulated. At 24 hours 5 genes were upregulated (t-statistic \> 6) and 10 genes downregulated (t-statistic \< -6, table [4](#T4){ref-type="table"}), and at 48 hours 1 gene was upregulated (t-statistic \> 6) and 15 genes downregulated (t-statistic \< -6, table [5](#T5){ref-type="table"}). At 24 hours, upregulated genes included *NFKBIA*, an inhibitor of NF-ΚB, and *TRIM74*, which was sustained at 48 hours, the significance of which is uncertain. Downregulated genes were those involved in cell cycle progression, including *CCNF*at 24 hours, and *CCNF*, *CDC20*and *AURKA*at 48 hours, consistent with growth arrest.

###### 

Genes regulated 24 hours following dexamethasone treatment.

  ProbeSet ID         Gene        t       P          FDR      Definition
  ------------------- ----------- ------- ---------- -------- ----------------------------------------------------------
  **Upregulated**                                             
  ILMN_3930687        FAM112A     6.67    1.32E-06   0.0091   family with sequence similarity 112, member A
  ILMN_6620255        TRIM74      6.29    3.06E-06   0.0132   tripartite motif-containing 74
  ILMN_4280113        NFKBIA      6.23    3.48E-06   0.0138   nuclear factor kappa B inhibitor, alpha
  ILMN_2140136        EMR2        6.10    4.65E-06   0.0149   egf-like containing, mucin-like, hormone receptor-like 2
  ILMN_7000397        ANKRD15     6.08    4.91E-06   0.0149   ankyrin repeat domain 15
  **Downregulated**                                           
  ILMN_870524         HOXB8       -8.60   2.53E-08   0.0011   homeo box B8
  ILMN_4830520        LOC144501   -6.72   1.19E-06   0.0091   hypothetical protein LOC144501
  ILMN_6110332        ARHGAP19    -6.70   1.24E-06   0.0091   Rho GTPase activating protein 19
  ILMN_2970619        ESPL1       -6.65   1.38E-06   0.0091   extra spindle pole bodies homolog 1
  ILMN_3130541        CCNF        -6.64   1.43E-06   0.0091   cyclin F
  ILMN_4760577        CENPA       -6.62   1.46E-06   0.0091   centromere protein A
  ILMN_4810646        PIF1        -6.54   1.76E-06   0.0095   PIF1 5\'-to-3\' DNA helicase homolog
  ILMN_1070762        PSRC1       -6.40   2.38E-06   0.0114   proline/serine-rich coiled-coil 1
  ILMN_4860703        LOC648695   -6.19   3.82E-06   0.0138   retinoblastoma binding protein 4
  ILMN_1110538        INCENP      -6.05   5.19E-06   0.0149   inner centromere protein antigens 135/155 kDa

t, t-statistic; and FDR, false discovery rate

###### 

Genes regulated 48 hours following dexamethasone treatment.

  ProbeSet ID         Gene        t       P          FDR      Definition
  ------------------- ----------- ------- ---------- -------- ------------------------------------------------------
  **Upregulated**                                             
  ILMN_6620255        TRIM74      6.30    3.01E-06   0.0089   tripartite motif-containing 74
  **Downregulated**                                           
  ILMN_4810646        PIF1        -8.85   1.58E-08   0.0004   PIF1 5\'-to-3\' DNA helicase homolog
  ILMN_870524         HOXB8       -8.66   2.26E-08   0.0004   homeo box B8
  ILMN_1450193        LGALS1      -8.57   2.66E-08   0.0004   lectin, galactoside-binding, soluble, 1 (galectin 1)
  ILMN_4760577        CENPA       -7.64   1.71E-07   0.0018   centromere protein A
  ILMN_4730605        AURKA       -7.47   2.42E-07   0.0021   aurora kinase A
  ILMN_1500010        CDC20       -6.84   9.09E-07   0.0053   CDC20 cell division cycle 20 homolog
  ILMN_4060064        HMMR        -6.82   9.61E-07   0.0053   hyaluronan-mediated motility receptor
  ILMN_2070408        MID1        -6.80   9.97E-07   0.0053   midline 1 (Opitz/BBB syndrome)
  ILMN_2070288        MT1E        -6.66   1.36E-06   0.0065   metallothionein 1E
  ILMN_1070762        PSRC1       -6.60   1.55E-06   0.0067   proline/serine-rich coiled-coil 1
  ILMN_150543         C20orf129   -6.46   2.12E-06   0.0077   chromosome 20 open reading frame 129
  ILMN_5870193        FAM64A      -6.45   2.14E-06   0.0077   family with sequence similarity 64, member A
  ILMN_2810201        KIF14       -6.34   2.77E-06   0.0089   kinesin family member 14
  ILMN_1050195        KIF20A      -6.28   3.11E-06   0.0089   kinesin family member 20A
  ILMN_3130541        CCNF        -6.05   5.21E-06   0.0131   cyclin F

t, t-statistic; and FDR, false discovery rate

Functional analysis using GSEA and meta-GSEA on the expression profiles obtained at 8 hours and 24 hours after dexamethasone treatment (additional files [1](#S1){ref-type="supplementary-material"} and [2](#S2){ref-type="supplementary-material"}), revealed a significant upregulation of metabolic pathways, particularly adipogenesis at 8 hours, and a marked effect on pathways associated with cell cycling and proliferation, particularly downregulation of C-MYC at 8 hours and NF-ΚB at 24 hours, and upregulation of apoptotic pathways at 24 hours. Glucocorticoids are known to have effects on multiple cellular metabolic pathways, including glucose and carbohydrate metabolism, and have pro-adipogenic effects \[[@B38]\]. Suppression of C-MYC is a critical step prior to the initiation of apoptosis by dexamethasone in ALL \[[@B39]\] and suppression of NF-ΚB has been described \[[@B40]\].

To determine whether the molecular response to glucocorticoids in this xenograft model of ALL mimicked the effects seen in either glucocorticoid-treated patients with ALL \[[@B16]\] or cell-line models of ALL \[[@B13]\], we applied parametric gene set enrichment analysis (PGSEA) \[[@B28]\]. Comparing gene expression profiles from multiple experiments is notoriously difficult and typically any true similarities are swamped by technical differences in microarray vendor, normalization strategies and analytical approach. By summarizing genes at the gene set level (such as genes in the same pathway), these technical differences are mitigated, allowing comparison of samples from multiple studies.

We performed PGSEA on the 6-8 hour samples from the 3 studies, and then two-dimensional hierarchical clustering to identify the relationships between the different ALL models (Figure [2](#F2){ref-type="fig"} and annotated in additional file [3](#S3){ref-type="supplementary-material"}). This revealed considerable heterogeneity in the molecular response to glucocorticoids in patients into at least 2, and possibly 4 different groups (green bars, Figure [2](#F2){ref-type="fig"}), which may represent different modes of response to glucocorticoids in patients. Relative to this inter-patient heterogeneity, both cell lines (purple bars, Figure [2](#F2){ref-type="fig"}) and xenografts (black bars, Figure [2](#F2){ref-type="fig"}) are remarkably reproducible; we anticipate that adding additional xenograft models of ALL from distinct patients will mirror the heterogeneity of the patient from whom they were derived. It is also evident that overall, glucocorticoid-treated xenografts co-cluster with a group of 3 patients (B-ALL-37, -38, and -40), all of whom had BCP-ALL and a good early prednisolone response, with varied cytogenetics (hyperploidy, t(12;21), and normal respectively). At more relaxed clustering thresholds, the glucocorticoid-treated xenografts cluster with 4 other patients with BCP-ALL (B-ALL-24, -31, -33, and 43) and the cell lines.

![**Parametric GSEA of combined top 100 glucocorticoid-induced gene sets with greatest variance from xenograft, patient and cell line models**. Hierarchical clustering with gene sets in rows, samples in columns (xenografts - black, patient - green, cell line - purple). Each colour of each cell represents the Z-score (see legend). Boxes 1-5 represent defined clusters.](1471-2164-12-565-2){#F2}

We identified 5 clusters of gene sets with distinct expression profiles, each behaving differently in the 3 models of ALL. Cluster 1 demonstrated the markedly heterogeneous patterns seen in patient samples, with the xenograft samples showing a pattern similar to 8 of the patients; cluster 2 showed genesets that showed strong enrichment in the cell line study, and included a number of genesets associated with cell proliferation; cluster 3 did not show any striking differences across the three ALL models; cluster 4 showed genesets downregulated in both xenografts and cell lines compared to the patient samples, and included a number genesets associated with cell cycle progression, DNA/RNA replication and MYC; cluster 5 showed genesets strongly downregulated in the xenograft and cell line models, and included genesets associated with MYC and metabolic processes, particularly catabolism and energy production. In this limited comparison, it is clear that glucocorticoid-induced gene expression patterns seen in ALL are dependent on the experimental model, and that the patterns derived from the xenograft model show a greater similarity to patient-derived data than to cell lines.

A search of the TRANSFAC database v8.3 \[[@B41]\] of CoMoDis \[[@B42]\] identified GRE motifs (within 100 kb either side of the gene) in only 25 (14.5%) of the top 173 upregulated genes at the 8 hour timepoint in this study, and no GRE motifs were identified in the upregulated genes at 24 or 48 hours. This supports accumulating evidence that glucocorticoids exert long-range effects through very distal steroid receptor binding sites \[[@B43]\]. Analysis of significantly differentially expressed glucocorticoid-induced genes in an *in vitro*cell line study \[[@B13]\] revealed a similar number of early response genes after 6 hours of exposure (60 upregulated (t-stat \> 10) and 27 downregulated (t-stat \< -10)) but a significantly greater number of genes after 24 hours (593 upregulated (t-stat \> 10) and 782 downregulated (t-stat \< -10)). Interestingly, all but 2 of the genes upregulated at 6 hours remained significantly upregulated at 24 hours, and 17 of the downregulated genes at 6 hours remained downregulated at 24 hours. GRE motifs were identified in 15 (25.0%) of the top 60 upregulated genes at 6 hours, and 87 (14.6%) of the top 593 genes at 24 hours. The observed difference between the studies in gene expression at later timepoints is consistent with continuous rather than physiological glucocorticoid exposure. In addition, in the cell line study, the GR (NR3C1) undergoes highly significant early and sustained autoupregulation, which in the continuous presence of ligand drives downstream gene expression. In contrast, in the xenograft model minimal GR upregulation is seen at the early timepoint but no significant change in GR expression is seen at either of the later timepoints.

Given the good statistical power observed in Figure [1A](#F1){ref-type="fig"}, we proceeded to determine whether we could use fewer replicates and still identify a majority of the differentially expressed genes. Replicate analysis (Figure [3](#F3){ref-type="fig"}) revealed that at the 8 hour dexamethasone-treated timepoint, a dataset with high signal and differential expression, using data from any 3 randomly chosen biological replicates instead of 4 resulted in excellent recovery scores of \> 0.9. That is, on average, 90% of the differentially expressed genes identified from all 4 samples were also identified in any combination of 3 arrays. At 24 hours, a timepoint with less signal, the average recovery score was 0.85 with 3 replicates, but was more variable than at 8 hours. Using just 2 biological replicates recovered 88% of the list of differentially expressed genes at 8 hours, which dropped to 14% at 24 hours. This confirms that the 8 hour time point has the strongest signal, which is reproducible across different subsets of biological replicates. We recommend using a minimum of 3 biological replicates, since fewer replicates destabilized our ability to identify differentially expressed genes. This has important considerations for experimental design, and has significant implications on cost and animal numbers.

![**Recovery scores at 8 hours and 24 hours when randomly selecting all combinations of 3 replicates (3rep) or 2 replicates (2rep) from the set of 4 biological replicates**. The Recovery Score represents the proportion of differentially expressed genes from all 4 replicates recovered when using fewer replicates.](1471-2164-12-565-3){#F3}

Conclusions
===========

We conclude that the NOD/SCID ALL xenograft mouse model provides biologically relevant insights into glucocorticoid-induced gene expression, in a consistent, reproducible and clinically relevant model system. We have demonstrated that the 8 hour timepoint provides the highest number of significantly differentially expressed genes, that time-matched controls are redundant and excellent recovery scores can be obtained with 3 replicates. We have thus established the optimal experimental design, with subsequent important implications for costs and animal numbers.
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